A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
← catalyst calendarSponsored by CNS Pharmaceuticals, Inc. (industry) · CNSP — their whole pipeline →. With Worldwide Clinical Trials.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
252actual
Sites
48
Countries
France, Italy, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-18 | actual | When the study began enrolling |
| Primary completion | 2026-04-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma Multiforme, Adult
Interventions
- Drug: Berubicin — also filed as Berubicin Hydrochloride
- Drug: Lomustine — also filed as Lomustine Capsules, CCNU, CeeNU, Gleostine
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Through study completion an average of 4 years.
Permalink · CNSP's whole pipeline · Catalyst calendar · Every registered study · What changed